Tissue Regenix (LON:TRX) remains on course to launch its DermaPure product in the US market next year after its US partner passed a significant milestone.
Community Tissue Services (CTS), the UK company’s processing partner in the United States, has successfully undertaken its first production of DermaPure, Tissue Regenix's dCELL human dermis application.
The success follows just four months after the signing of the processing agreement, and leaves Tissue Regenix on track to address the highly lucrative US wound healing market in the first half of next year.
CTS is now in a position to produce DermaPure from decellularised human biological scaffolds for patients suffering from acute and chronic wounds.
"A lot has already been achieved with CTS in a relatively short amount of time and this is because of both organisations' clear commitment to developing transformational regenerative medical devices that could benefit patients,” said Greg Bila, president of Tissue Regenix Wound Care.
Tissue Regenix issued well-received interim results last week in which it noted it is nearing completion of the appointment of distributors across the US to cover the majority of the country.